BRISTOL MYERS SQUIBB

🇫🇷France

Country: 🇫🇷France

Ownership: -

Established: 1989-01-01

Employees: 30K

Market Cap: $97.5B

Website: https://www.bms.com/

Clinical Trials

A Dose Ranging Phase IIa Study of 6 Hour Intravenous Dosages of CXL-1427 in Patients Hospitalized With Heart Failure

Phase 2

Completed

Conditions: Heart Failure
Decompensated Heart Failure
Acute Heart Failure

Interventions: Drug: Placebo
Drug: CXL-1427

First Posted Date: 2014-06-06

Last Posted Date: 2019-07-31

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 70

Registration Number: NCT02157506

Locations: 🇷🇺
Cardioxyl Study Site, Tomsk, Russian Federation
🇵🇱
Cardioxyl Study SIte, Warsaw, Poland

A Blinded Study to Evaluate Effect on Atrial Fibrillation Burden in Patients With Paroxysmal Atrial Fibrillation

Phase 2

Terminated

Conditions: Paroxysmal Atrial Fibrillation

Interventions: Drug: Placebo (Matching with BMS-919373)
Drug: BMS-919373

First Posted Date: 2014-06-05

Last Posted Date: 2019-07-31

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 158

Registration Number: NCT02156076

Locations: 🇺🇸
Wcct Global, Llc, Costa Mesa, California, United States
🇺🇸
Long Beach Va Medical Center, Long Beach, California, United States
🇺🇸
Community Clinical Research Center, Anderson, Indiana, United States

and more 22 locations

A Single-Arm, Open-Label, Multicenter Clinical Trial With Nivolumab (BMS-936558) for Subjects With Histologically Confirmed Stage III (Unresectable) or Stage IV Melanoma Progressing Post Prior Treatment Containing an Anti-CTLA4 Monoclonal Antibody (CheckMate 172)

Phase 2

Completed

Conditions: Melanoma

Interventions: Drug: Nivolumab (BMS-936558)

First Posted Date: 2014-06-05

Last Posted Date: 2020-09-11

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 1009

Registration Number: NCT02156804

Locations: 🇬🇧
Local Institution, Wirral, United Kingdom
🇪🇸
Hospital De Madrid, Norte Sanchinarro, Madrid, Spain
🇪🇸
Hospital Clinico Univ. de Santiago-CHUS, Santiago de Compostela, Spain

and more 5 locations

Study of the Effects of BMS-919373 on the Electrical Activity of the Heart Using Pacemakers

Phase 1

Terminated

Conditions: Atrial Fibrillation

Interventions: Drug: BMS-919373
Drug: Sotalol
Drug: Placebo for BMS-919373

First Posted Date: 2014-06-03

Last Posted Date: 2023-12-19

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 7

Registration Number: NCT02153437

Locations: 🇨🇦
Local Institution - 0001, Toronto, Ontario, Canada
🇨🇦
Local Institution, Montreal, Quebec, Canada
🇨🇦
The University Of Calgary, Calgary, Alberta, Canada

and more 2 locations

Early Post-marketing Study of Eliquis (Apixaban)

Withdrawn

Conditions: Non-valvular Atrial Fibrillation (NVAF)

Interventions: Drug: Apixaban

First Posted Date: 2014-06-03

Last Posted Date: 2016-08-17

Lead Sponsor: Bristol-Myers Squibb

Registration Number: NCT02153424

Locations: 🇲🇽
Local Institution, Puebla, Mexico

Expanded Access Program With Nivolumab to Treat Melanoma

Conditions: Stage III (Unresectable) or Stage IV Advanced Melanoma

First Posted Date: 2014-05-20

Last Posted Date: 2016-09-29

Lead Sponsor: Bristol-Myers Squibb

Registration Number: NCT02142218

Locations: 🇺🇸
Cancer Specialists Of North Florida, Jacksonville, Florida, United States
🇺🇸
Oncology Hematology Associates Of Sw In, Newburgh, Indiana, United States
🇺🇸
Mount Sinai Comprehensive Cancer Center, Miami Beach, Florida, United States

and more 18 locations

Regimen Optimization Study

Phase 2

Completed

Conditions: Kidney Transplantation

Interventions: Drug: Thymoglobulin
Drug: mycophenolate mofetil(MMF)
Drug: Belatacept
Drug: Corticosteroids
Drug: Everolimus(EVL)
Drug: Tacrolimus(TAC)

First Posted Date: 2014-05-13

Last Posted Date: 2021-06-22

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 58

Registration Number: NCT02137239

Locations: 🇺🇸
Emory Univeristy, Atlanta, Georgia, United States
🇺🇸
University Of Illinois, Chicago, Illinois, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

and more 17 locations

UNITY 3: A Japanese Phase 3 Study of a Daclatasvir/Asunaprevir/BMS-791325 in Subjects With Genotype 1 Chronic Hepatitis C

Phase 3

Completed

Conditions: Hepatitis C Virus Infection

Interventions: Drug: DCV 3DAA
Drug: Daclatasvir
Drug: Asunaprevir
Other: Placebo for Daclatasvir
Other: Placebo for Asunaprevir
Other: Placebo for DCV 3DAA

First Posted Date: 2014-04-25

Last Posted Date: 2015-09-18

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 297

Registration Number: NCT02123654

Locations: 🇯🇵
Local Institution, Saga, Japan

Absolute Bioavailability of BMS-791325

Phase 1

Completed

Conditions: Hepatitis C Virus Infection

Interventions: Drug: BMS-791325
Drug: [13C]-BMS-791325

First Posted Date: 2014-04-11

Last Posted Date: 2014-06-26

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 8

Registration Number: NCT02112110

Locations: 🇬🇧
Local Institution, Nottingham, Nottinghamshire, United Kingdom

Long Term Experience With Abatacept in Routine Clinical Practice

Completed

Conditions: Rheumatoid Arthritis

Interventions: Drug: Abatacept

First Posted Date: 2014-04-10

Last Posted Date: 2017-04-19

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 2364

Registration Number: NCT02109666

Locations: 🇨🇭
Local Institution, Basel, Switzerland

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy